Synta-66

Synta-66 is a potent and selective small molecule inhibitor of ORAI1, the pore-forming subunit of the calcium release-activated calcium (CRAC) channel. It specifically blocks store-operated calcium entry (SOCE), a critical mechanism in non-excitable cells where the depletion of endoplasmic reticulum calcium stores triggers the influx of extracellular calcium. By inhibiting SOCE, Synta-66 modulates various calcium-dependent signaling pathways involved in gene expression, mediator release, and cell proliferation. Preclinical research has demonstrated its potential in treating a wide range of conditions, including asthma (by inhibiting mast cell degranulation), Alzheimer's disease and type 2 diabetes-induced dementia (by reducing amyloidogenesis and neuroinflammation), and various cancers and fibrotic diseases. It was originally developed by Synta Pharmaceuticals and is widely utilized as a pharmacological tool to investigate ORAI1-mediated signaling.

Other names

Synta 66Synta66Synta-66ORAI1 inhibitor Synta-66ORAI-1 inhibitor Synta-66ORAI 1 inhibitor Synta-66